Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level. The reason for the recall is that there is a potential that patches ...

Patch testing, if performed, was not reported. In addition, 0.7% reported pruritus, and 0.5% reported an erythematous rash. [19] Several patients with ACD from a buprenorphine TTS have also been ...

From acne to chronic pain relief, the market for transdermal patches is growing. Lounge explores the science, and reasons for ...

For example, with the buprenorphine transdermal patch, you apply the patch to your skin every seven days. Regardless of the ...

During the COVID-19 pandemic, when fentanyl overdoses surged, doctors were desperate to find ways of helping their patients.

AVERSA™ Fentanyl Advances Toward Commercialization Our lead product, AVERSA™ Fentanyl, is poised to become the world’s first abuse-deterrent opioid transdermal patch. We made significant ...